Udenafil

Legal statusLegal status Pharmacokinetic dataProtein binding93,9%MetabolismLiver (mainly CYP3A4)Elimination half-life7.3–12.1 hoursExcretionBiliaryIdentifiersCAS NumberPubChem CIDDrugBankChemSpiderUNIIKEGGChemical and physical dataFormulaC₂₅H₃₆N₆O₄SMolar mass516.66 g·mol⁻¹3D model (JSmol) ^NY (what is this?)  (verify)

The drug udenafil is marketed under the trade name Zydena. It is within the PDE₅ inhibitor class (which also includes avanafil, sildenafil, tadalafil, and vardenafil). Like other PDE₅ inhibitors, it is used to treat erectile dysfunction. Udenafil was developed by Dong-A Pharmaceutical.^[1] It has fairly rapid onset of action (peak plasma concentration after 1 to 1.5 hours), and has long duration of action (plasma half-life of 11 to 13 hours). Udenafil's pharmacokinetics allows once-daily dosage (in addition to on-demand use).^[2] Typical doses are 100 and 200 mg. Udenafil is available in Korea, Russia, and the Philippines.^[3] It has not yet been approved for use in the United States by the U.S. Food and Drug Administration.

References